Both ulcerative colitis and familial polyposis are colonic mucosal diseases which are known to predispose to colon cancer. While colonoscopy is an accurate modality used in screening and surveillance for patients with these two diseases, patients continue to present with colon cancer with these known premalignant diseases. This study was conducted to ascertain why patients with known premalignant disease still develop life-threatening colon cancer and to assess the clinical profile and prognosis of patients with known ulcerative colitis (UC) and familial polyposis coli (FPC) who subsequently develop colon cancer. Total colectomy, mucosal proctectomy, and ileoanal pullthrough was performed on 367 patients with UC and FPC between January 1982 and March 1993 at our institution. Of these, 15 had invasive adenocarcinoma of the colon (4.1%) in addition to the primary disease. These 15 patients were studied in detail. The average duration of disease from diagnosis to definitive treatment of cancer was 17 years. Thirteen of the patients in this series had UC (87%), while only 2 had FPC (13%). Colonoscopy was used to make the diagnosis in 11 patients (73%), while the diagnosis was made only at the time of surgery in 3 (20%). Nine of the patients presented with a Dukes' B2 cancer or worse, representing 60% of the series. A high percentage had synchronous invasive cancers in this series--6 patients (40%). Despite the relatively high percentage of advanced cancers in this series, at a mean follow-up of 47.1 months, 14 of the 15 patients are still living. One patient has known recurrent disease while 1 has an elevated CEA with no other evidence of recurrence.(ABSTRACT TRUNCATED AT 250 WORDS)

Download full-text PDF

Source
http://dx.doi.org/10.1006/jsre.1994.1148DOI Listing

Publication Analysis

Top Keywords

colon cancer
20
patients
12
patients premalignant
8
colonic mucosal
8
mucosal diseases
8
ulcerative colitis
8
colitis familial
8
familial polyposis
8
high percentage
8
cancer
7

Similar Publications

Impact of surgical specialization on long-term survival after emergent colon cancer resections.

Scand J Surg

January 2025

Department of Surgery, Helsingborg Hospital, Clinical Sciences Lund, Lund University, Lund, Sweden.

Background: The impact of surgical specialization on long-term survival in patients undergoing emergent colon cancer resections remains unclear.

Method: A retrospective analysis was conducted on all patients who underwent emergent colon cancer resections at a secondary care hospital between 2010 and 2020. The most senior surgeon performing the procedures was classified as colorectal surgeon (CS) or non-colorectal surgeon (NCS).

View Article and Find Full Text PDF

Ischemic colitis (IC) is a multifaceted condition that often manifests with nonspecific symptoms such as abdominal pain and bloody diarrhea, particularly in older adults with vascular risk factors. Diagnosis is supported by elevated levels of white blood cells, lactate, and C-reactive protein (CRP). Computed tomography (CT) imaging typically reveals wall thickening and fat stranding in watershed areas.

View Article and Find Full Text PDF

Objective: Minor ginsenosides have demonstrated promising anticancer effects in previous reports. Total minor ginsenosides (TMG) were obtained through the fermentation of major ginsenosides with , and potential anticancer effects of TMGs on the mouse colon cancer cell line CT26.WT, and , were investigated.

View Article and Find Full Text PDF

Different types of cancers affect the gastrointestinal tract (GIT), starting from the oral cavity and extending to the colon. In general, most of the current research focuses on the systemic delivery of the therapeutic agents, which leads to undesired side effects and a limited enhancement in the therapeutic outcomes. As a result, localized delivery within gastrointestinal (GI) cancers is favorable in overcoming these limitations.

View Article and Find Full Text PDF

Background: While hepatocellular carcinoma (HCC) remains the leading cause of liver transplant (LT) for liver tumors, indications have broadened over the years. Data regarding patient characteristics and outcomes of LT for liver tumors are limited.

Methods: From Jan-2002 to March-2022, 14,406 LT recipients for various liver tumors were identified in United Network for Organ Sharing database.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!